MedPath

Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression

Terminated
Conditions
Major Depressive Disorder
Registration Number
NCT01579942
Lead Sponsor
Massachusetts General Hospital
Brief Summary

The investigators are doing this study to find out if they can use electroencephalographic (EEG) recordings, which measure brain waves, to predict response to antidepressant treatments, as well as to distinguish patients who have depression from those who do not. In particular the investigators want to test the usefulness of a new type of analysis of EEG recordings called brain network activation or BNA. BNA allows to identify patterns of activation in brain networks and to track their changes over time.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • • Male and female outpatients, aged 18-55 years

    • Subjects meeting full criteria for the diagnosis of current Major Depressive Disorder (MDD) without psychotic features, as determined by clinical evaluation and Mood Module of structured diagnostic interview (SCID), completed by the study clinician.
    • HAM-D17 score of 14 or higher
    • Able to provide informed consent
    • Right handed, normal (corrected) vision and normal hearing
Exclusion Criteria
  • • Other primary diagnoses including major depressive disorder with psychotic features, bipolar disorder, schizoaffective disorder, schizophrenia, dementia, attention deficit hyperactivity disorder (ADHD).

    • Substance use disorder (abuse or dependence with active use within the last 6 months).
    • Significant sensory deficits such as deafness or blindness.
    • Severe or unstable medical illness, including history of closed head injury resulting in loss of consciousness, seizure disorder; history of neurological disorders.
    • Pregnant or nursing females who are not using an accepted method of contraception (birth control pill, IUD, combination of barrier methods)
    • Clinically significant abnormal laboratory values or electrocardiogram For Healthy Controls

Inclusion Criteria:

  • Males and females, aged 18-55 years
  • Subjects who do not meet full criteria for any of the major psychiatric diagnosis including MDD, bipolar disorder, schizophrenia, substance abuse/dependence, attention deficit hyperactivity disorder (ADHD), as determined by clinical evaluation and structured diagnostic interview, completed by the study clinician.
  • Right handed, normal (corrected) vision and normal hearing

Exclusion Criteria:

  • Any current primary psychiatric, or medical condition determined to be clinically significant.
  • Current use of psychotropics or any medication with clinically significant central nervous system effects.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Brain Network Analysis group patterns8 weeks

The investogators will make a comparison of Functional networks of brain activity (BNA™) in subjects with MDD and healthy individuals measured using analysis of EEG Event Related Potential (ERP) data \[ Time Frame: Baseline, 1 week after the first dose of antidepressant treatment, end of the treatment phase\].

Secondary Outcome Measures
NameTimeMethod
Identify possible predictors of treatment response8 weeks

The investigators will examine the agreement between clinical diagnoses and the change of Brain Network Activation (BNA™)Scores in MDD subjects and healthy controls.

Subjects will undergo clinical diagnostic interviews and a comprehensive neuropsychological and cognitive assessment, and then complete 1 EEG scan of approximately 1 hour. The results of the BNA will be compared to the results of the clinical diagnostic interviews and tests.

Trial Locations

Locations (1)

Depression Clinical and Research Program

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath